Synapse - Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC) Meeting Abstract

Authors:	Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Bajorin, D. F.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; Funt, S. A.; Shah, N. J.; Iyer, G.; Aggen, D. H.; Teo, M. Y.; Ostrovnaya, I.; Rosenberg, J. E.
Abstract Title:	Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC)
Meeting Title:	2024 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	42
Issue:	16 Suppl.
Meeting Dates:	2024 May 31-Jun 4
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2024-06-01
Language:	English
ACCESSION:	WOS:001275557401224
PROVIDER:	wos
DOI:	10.1200/JCO.2024.42.16_suppl.4581
Notes:	Meeting Abstract: 4581 -- Source: Wos